MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Vulvovaginal Candidiasis
Interventions
DRUG

MGCD290

1 Oral Dose Administration

Trial Locations (19)

11203

SUNY Downstate Medical Center, Brooklyn

15213

Magee-Womens Hospital of UPMC, Pittsburgh

19102

Drexel University College of Medicine, Philadelphia

23502

Tidewater Physicians for Women, Norfolk

27103

Lyndhurst Clinical Research, Winston-Salem

27607

Lyndhurst Clinical Research, Raleigh

29403

Medical University of South Carolina, Charleston

33161

Healthcare Clinical Data, Inc., North Miami

33461

Altus Research, Lake Worth

35294

University of Alabama at Birmingham, Birmingham

48201

Harper University Hospital, Detroit

70006

Clinical Trials Management, LLC, Metairie

70433

Clinical Trials Management, Covington

75061

Brownstone Clinical Trials, Irving

84070

Physician's Research Options, Sandy City

89123

Clinical Research of Nevada, Las Vegas

92123

Women's Health Care Research Corp., San Diego

98104

University of Washington, Seattle

30912-3500

Georgia Health Sciences University, Augusta

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MethylGene Inc.

INDUSTRY